Screening for medium chain acyl-CoA dehydrogenase deficiency is being evaluated

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7293.1062 (Published 28 April 2001) Cite this as: BMJ 2001;322:1062
  1. Scott Grosse, health economist (bpagon@u.washington.edu)
  1. Office of Planning, Evaluation, and Legislation, National Center for Environmental Health, US Centers for Disease Control and Prevention, Mail Stop F-29, Atlanta, GA 30341, USA

    EDITOR—Tanner et al write that the effectiveness of screening neonates for medium chain acyl-CoA dehydrogenase deficiency has still not been completely evaluated.1 Evaluation of population based screening is a two part process. Firstly, the likely benefits and costs are assessed before the screening is introduced; and, secondly, an investigation is subsequently done into whether these calculations are borne out in practice.

    The United Kingdom's health technology assessment process has undertaken the first step of its evaluation process …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription